Anupam Dalal - Aug 26, 2021 Form 4/A - Amendment Insider Report for Aadi Bioscience, Inc. (AADI)

Role
Director
Signature
/s/ Neil Desai, as Attorney-in-Fact
Stock symbol
AADI
Transactions as of
Aug 26, 2021
Transactions value $
$19,999,990
Form type
4/A - Amendment
Date filed
8/31/2021, 07:52 PM
Date Of Original Report
Aug 30, 2021
Previous filing
Jul 2, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AADI Common Stock Purchase $20M +1.53M $13.08 1.53M Aug 26, 2021 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 1,284,698 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 244,704 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.
F2 This amendment is filed to correct footnote (1) included in the Form 4 filed August 30, 2021.